Recurrent Gastric Cancer Completed Phase 2 Trials for Bortezomib (DB00188)

Also known as: Gastric cancer recurrent / Stomach cancer recurrent / Stomach carcinoma recurrent / Gastric carcinoma recurrent

IndicationStatusPhase
DBCOND0028800 (Recurrent Gastric Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00061932Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or StomachTreatment